Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens

Scandinavian Journal of Immunology

Volumn 43, Issue 4, 1996, Pages 431-438

  Kirkley, J E ^a   Goldstein, A L ^b   Naylor, P H ^c  

^a KNOX COLLEGE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; IMMUNOLOGICAL ADJUVANT; MONTANIDE CSA 720; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029868650     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-60.x     Document Type: Article

References (38)

1. Brown F. Recombinant sub-unit and peptide viral vaccines. In: Gregoriadis G, Allison AL, Poste G, eds. Immunological Adjuvants and Vaccines. New York: Plenum Press, 1989:163-73.
2. Zavala F, Tam JP, Hollingdale MR et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria vaccine. Science 1985;228:1436-40.
3. Berzofsky JA. Development of artificial vaccines against HIV using defined epitopes. FASEB J 1991;5:2412-18.
4. Naylor PH, Sztein MB, Wada S et al. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine - HGP-30-KLH. Int J Immunopharmac 13, Suppl 1991;1:117-27.
5. Kovacs JA, Vasudevacharim B, Easter M et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV seronegative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28.
6. Schwartz DH, Gorgse G, Clements ML et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-IIIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
7. Allison AC. Antigens and adjuvants for a new generation of vaccines. In: Gregoriadis G, Allison AL, Poste G, eds. Immunological Adjuvants and Vaccines. New York: Plenum Press, 1989:1-12.
8. Nicholson KG, Tyrrell DAJ, Harrison P et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological and clinical reactions. J Biol Stand 1979;7:123-36.
9. Berzofsky JA. Approaches and issues in the development of vaccines against HIV. J AIDS 1991;4:451-9.
10. Edelman R, Tacket CO. Adjuvants. Intern Rev Immunol 1990;7:51-66.
11. Geerligs HJ, Weijer WJ, Welling GW, Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J Immunol Meth 1989;124:95-102.
12. Hart MK, Palker TJ, Matthews TJ et al. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in Rhesus monkeys. J Immunol 1990;145:2677-85.
13. Jones GL, Spencer L, Lord R, Mollard R, Pye D, Saul A. Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity. Immunol Letters 1990;24:253-60.
14. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofksy JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs Nature 1990;344:873-5.
15. Hart MK, Weinhold KJ, Scearce RM et al. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci 1991;9448-52.
16. Kirkley JE, Naylor PH, Marciani DJ, Kensil CR, Newman M, Goldstein AL. QS-21 augments the antibody response to a synthetic peptide vaccine compared with alum. In: Goldstein AL, Garaci E, eds. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. New York: Plenum Press, 1992:231-6.
17. Fernandez IM, Snijders A, Benaissa-Trouw BJ, Harmsen M, Snippe H, Kraai Jeveld CA. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. J Virol 1993;67:5843-8.
18. Castrucci G, Ferrari M, Angelillo V, Rigonat F, Capodicasa L. Field evaluation of the efficacy of Romovac 50, a new inactivated adjuvanted bovine rolavirus vaccine. Comp Immunol Microbiol Infect Dis 1993;16:235-9.
19. Angela PA, Fernandes MJ, Hayashi Y, Germano PML, Burer SP. Preparation of rabies vaccine PV-BHK in oily emulsion and evaluation of immunogenic power in bovines. Arq Biol Tecnol (Curitiba) 1991;34:609-16.
20. Cook DR, Hill HY, Kinker DR. Efficacy of a killed GPX-deleted pseudorabies virus vaccine. Can J Vet Res 1990;54:438-45.
21. Wilier A, Achour A, Mbika JP et al. Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus. Biomed & Pharmacother 1992;46:359-65.
22. Jiang J-D, Chu F-N, Naylor PH et al. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection. J AIDS 1992;5:382-90.
23. Johnson RP, Trocha A, Yang L et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. J Immunol 1991;147:1512-21.
24. Wahren B, Rosen J, Sandstrom E, Mathiesen T, Modrow S, Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J AIDS 1989;4:448-56.
25. Naylor PH, Naylor CW, Badamchian M et al. Human immunodeficiency virus contains an epitope immunoreactive with thymosin a1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci 1987;84:2951-5.
26. Boucher CAB, Krone WJA, Goudsmit J et al. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30. J Clin Lab Anal 1990;4:43-7.
27. Hughes BW, Kenney JS, Allison AC. Measurement of antibody affinity, concentration and isotype to evaluate antigens, affinity, and immunization regimens in vaccine research. In: Gregoriadis G, Allison AL, Poste G, eds. Immunological Adjuvants and Vaccines. New York: Plenum Press, 1989:203-12.
28. Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype, and epitope specificity of murine antibodies. J Immunol Meth 1989;121:157-66.
29. Murray JS, Madri J, Tite J, Carding SR, Bottomly K. MHC control of CD4+ T cell subset activation. J Exp Med 1989;170:2135-40.
30. Pfeiffer C, Murray J, Madri J, Bottomly K. Selective activation of Th1- and Th2-like cells in vivo - Response to human collagen IV. Immunol Rev 1991;123:65-84.
31. Abrignani S, Montagna D, Jeannet M et al. Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc Natl Acad Sci 1990;87:6136-40.
32. Clerici M, Tacket CO, Via CS et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991;21:1345-9.
33. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140:4245-52.
34. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell: IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
35. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of Th1 and Th2 responses. Immunology Today 1991;12:A49-A53.
36. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
37. ten Hagen TLM, Sulzer AJ, Kidd MR, Lal AA, Hunter RL. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J Immunol 1993;151:7077-85.
38. Johnston BA, Eisen H, Fry D. An evaluation of several adjuvant emulsion regimens for the production of polyclonal antisera in rabbits. Lab Animal Science 1991;41:15-21.